TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06086275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: At each visit, the participant will receive a single dose of buprenorphine, either 0.15mg IV, 8mg PO, or 16mg PO. The order for the first dose administered will be fixed to the IV dose, and the subsequent doses will be randomized and counterbalanced to 8mg or 16mg PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: At each visit, the participant will receive a single dose of buprenorphine, either 0.15mg IV, 8mg PO, or 16mg PO. The order for the first dose administered will be fixed to the IV dose, and the subsequent doses will be randomized and counterbalanced to 8mg or 16mg PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: At each visit, the participant will receive a single dose of buprenorphine, either 0.15mg IV, 8mg PO, or 16mg PO. The order for the first dose administered will be fixed to the IV dose, and the subsequent doses will be randomized and counterbalanced to 8mg or 16mg PO.
Study: NCT06285461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-palatable meal
Description: Participants will consume a meal that corresponds to 40% of their daily resting metabolic rate and balanced diet but with low hedonic reward.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palatable meal
Description: Participants will consume a meal that corresponds to 40% of their daily resting metabolic rate and balanced diet but with high-hedonic reward.
Study: NCT06366100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy for Substance Use Disorder (DBT-SUD)
Description: In phase 1, DBT online training will consist of the following contents:~Block 1~1.1. Introduction to the key concepts 1.2. DBT-SUD program 1.3. Why DBT for alcohol addiction? 1.4. Proposed content for the group intervention.~Block 2~2.1. DBT skills training modules~In phase 2, DBT-SUD intervention will consist of about the following sessions:~GOALS OF SKILLS TRAINING AND MINDFULNESS:~S1: Goals of skills training; Observing, Describing and Participating~S2: Non-judgmentally, One-mindfulness, Effectively~DISTRESS TOLERANCE:~S3: Crisis Survival skills~S4: Crisis Survival and Radical Acceptance~ADDICTION SKILLS:~S5: Dialectical Abstinence.~S6: Clear Mind~S7: Burning Bridges-Building New Bridges~S8: Community Reinforcement~EMOTIONAL REGULATION:~S9: Identifying emotions and model of emotion~S10: Check the facts. Opposing Action~S11: Problem Solving. Reducing vulnerability~S12: Self-management and rehabilitation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Description: In phase 1, the UP training will have following contents:~Block 1~1.1. Introduction to key concepts 1.2. Why UP for alcohol addiction? 1.3. Dimensional assessment and case formulation. 1.4. Main characteristics of UP~Block 2~2.1. Modules of UP~In phase 2, UP intervention will consist of:~MOTIVATION:~S1: Motivation enhancement for treatment~UNDERSTANDING EMOTIONS:~S2: Understanding and model of emotions S3: Tracking emotional responses~MINDFULNESS:~S4: Emotion awareness~COGNITIVE FLEXIBILITY:~S5: Cognitive reappraisal to increase thinking flexibility~EMOTION DRIVEN BEHAVIORS:~S6: Emotional avoidance S7: Emotion-driven behaviors and alternative action~AWARENESS AND TOLERANCE:~S8: Tolerance of physical sensations~EMOTIONAL EXPOSURE:~S9: Interoceptive and situational emotion exposure S10: Exposure practice~RELAPSE PREVENTION:~S11: Relapse prevention S12: Review of progress
Study: NCT06276673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delfi
Description: Cuffs will be worn throughout the entire training session. Training session consist of lower intensity wall squats. Four sets of wall squats will be performed to failure. Arterial stiffness and muscle morphological assessments will be conducted before and after the exercise.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Delfi
Description: Cuffs will be worn throughout the entire training session. Training session consist of lower intensity wall squats. Four sets of wall squats will be performed to failure. Arterial stiffness and muscle morphological assessments will be conducted before and after the exercise.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delfi
Description: Cuffs will be worn throughout the entire training session. Training session consist of lower intensity wall squats. Four sets of wall squats will be performed to failure. Arterial stiffness and muscle morphological assessments will be conducted before and after the exercise.
Study: NCT05694130

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Oral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral Tacrolimus 1-2mg twice daily for 12 weeks.
Study: NCT05131022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948
Description: Oral NX-5948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948
Description: Oral NX-5948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948
Description: Oral NX-5948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948
Description: Oral NX-5948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948
Description: Oral NX-5948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948
Description: Oral NX-5948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948
Description: Oral NX-5948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948
Description: Oral NX-5948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948
Description: Oral NX-5948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948
Description: Oral NX-5948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948
Description: Oral NX-5948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948
Description: Oral NX-5948
Study: NCT05091216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine mouthwash
Description: The mouthwash used in this test is based on the records of past traditional Chinese medicine classics and the existing antibacterial experimental evidence. The selected medicinal materials are honeysuckle, scutellaria, peppermint, licorice, and rhizome.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dilute 50 times of Traditional Chinese Medicine mouthwash
Description: Dilute 50 times of traditional Chinese medicine mouthwash.
Study: NCT04167618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DTPA-omburtamab
Description: Biological, radiolabeled DPTA-omburtamab
Study: NCT05131022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948
Description: Oral NX-5948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948
Description: Oral NX-5948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948
Description: Oral NX-5948
Study: NCT06051864

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modius Mood Active Device
Description: Battery powered non-invasive neurostimulation device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Device
Description: Placebo comparator sham device (no active stimulation)
Study: NCT06260878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous Ringer's lactate
Description: Intravenous Ringer's lactate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous Ringer's lactate
Description: Intravenous Ringer's lactate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous Ringer's lactate
Description: Intravenous Ringer's lactate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous Ringer's lactate
Description: Intravenous Ringer's lactate
Study: NCT06068023

Intervention type: DRUG
Intervention: Folfirinox
Description: Patients meeting the criteria of post-operative adenocarcinoma of the ampulla of Vater will be enrolled, with adjuvant chemotherapy commencing within 8 weeks of recovery from surgery. Those undergoing palliative intent surgery or palliative chemotherapy are ineligible for the ADAPTA study.~The ADAPTA study's adjuvant chemotherapy involves 8-12 FOLFIRINOX cycles (Arm 2) repeated 2 weeks. Given patient outcomes, 8 cycles of FOLFIRINOX are deemed sufficient due to completion challenges in prior research. FOLFIRINOX regimen mirrors the modified version from the ACCORD/PRODIGE trial for metastatic pancreatic cancer. This trial adapts mFOLFIRINOX for standard practice.

Intervention type: DRUG
Intervention: Capox
Description: or 8 CAPOX cycles (Arm 1) every 3 weeks.
Study: NCT05629078

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toric intraocular lens Zeiss AT TORBI
Description: Intraocular lenses are medical devices that are implanted in patients during cataract surgery. At Plymouth University NHS trust the standard lens is a monofocal non-Toric lens unless the patient has astigmatism greater than 4.00D. This study involves implantation of a toric lens in the intervention group where astigmatism is greater than 1.00D. The lens is called the toric IOLS- Zeiss AT TORBI, will be implanted bilaterally instead of standard monofocal IOLs- Zeiss CT ASPHINA, used in routine cataract surgery within NHS.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toric intraocular lens Zeiss AT TORBI
Description: Intraocular lenses are medical devices that are implanted in patients during cataract surgery. At Plymouth University NHS trust the standard lens is a monofocal non-Toric lens unless the patient has astigmatism greater than 4.00D. This study involves implantation of a toric lens in the intervention group where astigmatism is greater than 1.00D. The lens is called the toric IOLS- Zeiss AT TORBI, will be implanted bilaterally instead of standard monofocal IOLs- Zeiss CT ASPHINA, used in routine cataract surgery within NHS.
Study: NCT05712434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long Intervention
Description: Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 2 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 6-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mid-length Intervention
Description: Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 4 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 4-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Intervention
Description: Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 6 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 2-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.
Study: NCT05942560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy-based intervention
Description: A specifically designed CBT-based intervention consisting of 8 weekly sessions with group format.~Each group will be comprised of 4-10 participants, and each session will last 1.5 hours.~The content of the weekly sessions will be based on Beck's cognitive theory and the cognitive therapy in groups guidelines.~The framework of every session will follow a pre-determined structure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational group
Description: The educational sessions are consisting of 8 weekly sessions with a group format. These sessions will focus on cancer-related information and care knowledge which will be delivered in daily routine care.
Study: NCT05720260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Hormone therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Hormone therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Hormone therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Hormone therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Hormone therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Hormone therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: AKT inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: AKT inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: immunotherapy
Study: NCT05734300

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Endoscopic Laparoscopic Surgery (CELS)
Description: The main surgical advantage in this procedure is the ability to view the colon intra- and extraluminal simultaneously. The laparoscopic approach enables manipulation and mobilization of the colon, while the endoscopic view secures that the resection is complete and not overlapping the ileac valve or creating stenosis.~Compared to the traditional oncological colon resection, the CELS resection is a minimally invasive procedure - organ sparing procedure leading to a reduced surgical stress response.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard resection
Description: In this study standard resection of the colon will be performed according to complete mesocolic excision (CME) principles.
Study: NCT04824950

Intervention type: OTHER
Group type: OTHER
Intervention: Circulating tumor DNA monitoring
Description: Monitoring of circulating tumor DNA after 2 and 4 cycles of chemotherapy
Study: NCT06114160

Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study: NCT06364475

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 16:8 Time-Restricted Intermittent Fasting Group
Description: Participants total daily energy expenditures were calculated using the Harris-Benedict formula. This group have a feeding window 8 hours and eating plan of 400 kcal lower than the total daily energy requirement and with similar macronutrient content (50% carbohydrates, 25% fat and 25% protein). Participants in the time-restricted eating group were allowed to drink calorie-free. They were expected to follow their diet for two months during the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Energy-Restricted Six-Meal Group
Description: Participants total daily energy expenditures were calculated using the Harris-Benedict formula. This group have an eating plan three meals and three snacks of 400 kcal lower than the total daily energy requirement and with similar macronutrient content (50% carbohydrates, 25% fat and 25% protein). They were expected to follow their diet for two months during the study.
Study: NCT05828173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter (LithiX Coronary HCIVLC; LithiX)
Description: Vessel preparation of moderately to severely calcified coronary artery lesions prior to stenting allows for full stent expansion and apposition to the vessel wall
Study: NCT05977439

Intervention type: DEVICE
Intervention: fMRI-EEG-TMS
Description: Participants will undergo a magnetic resonance imaging (MRI) scan with combined electroencephalography (EEG), and single-pulse transcranial magnetic stimulation (TMS) while completing cognitive flexibility (CF) and emotion recognition (CR) tasks.

Intervention type: DEVICE
Intervention: fMRI-EEG-TMS
Description: Participants will undergo a magnetic resonance imaging (MRI) scan with combined electroencephalography (EEG), and single-pulse transcranial magnetic stimulation (TMS) while completing cognitive flexibility (CF) and emotion recognition (CR) tasks.

Intervention type: DEVICE
Intervention: fNIRS-EEG-TMS
Description: Participants brain activity will be measured using functional near-infrared spectroscopy (fNIRS) with combined electroencephalography (EEG), and single-pulse transcranial magnetic stimulation (TMS) while completing cognitive flexibility (CF) and emotion recognition (CR) tasks.

Intervention type: DEVICE
Intervention: fNIRS-EEG-TMS
Description: Participants brain activity will be measured using functional near-infrared spectroscopy (fNIRS) with combined electroencephalography (EEG), and single-pulse transcranial magnetic stimulation (TMS) while completing cognitive flexibility (CF) and emotion recognition (CR) tasks.

Intervention type: DEVICE
Intervention: fNIRS-EEG-rTMS Interleaved with CBT
Description: Participants brain activity will be measured using functional near-infrared spectroscopy (fNIRS) with combined electroencephalography (EEG), and repetitive transcranial magnetic stimulation (rTMS). rTMS will be delivered via a MagVenture MagPro100 and Cool-B65 coil. The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold. The accelerated paradigm will consist 6 session a day for 5-6 days. Each rTMS session will be separated by 30 minutes of Cognitive Behavioral Therapy (CBT). rTMS treatment will be delivered at an individualized left DLPFC target based on each participant's individualized scans from prior neuroimaging sessions.
Study: NCT05711095

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified plant-based protein blend
Description: 20 grams of protein dissolved in 500 mL water from a non-transparent shaker

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant-based protein blend
Description: 20 grams of protein dissolved in 500 mL water from a non-transparent shaker
Study: NCT05527197

Intervention type: DEVICE
Group type: OTHER
Intervention: Lapiplasty
Description: The Lapiplasty® System instruments and implants will be retrospectively evaluated in patients previously surgically treated with the Lapiplasty® Procedure for Triplane MTP and TMT joint arthrodesis.
Study: NCT05490784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lee Silverman Voice Treatment BIG
Description: Patients assigned to experimental group will get Lee Silverman Voice Treatment BIG along with conventional treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: patients in this group will get conventional treatment program encompassing set of exercises such as complex motor sequences, stretching, dual tasking, mental imagery and core stability.
Study: NCT06500585

Intervention type: OTHER
Group type: OTHER
Intervention: Mill's Manipulation
Description: Mill's Manipulation: The therapist should apply a high-velocity low-amplitude thrust accompanied by a single application . Patients will be treated 3 times a week for 2 consecutive weeks.~Conventional Therapy:~Ultrasound therapy: Frequency: 1Mhz Pulse ultrasound: 1:4 Intensity: 1.5 W/cm2 Duration: 5 min.~Stretching of Wrist Extensors: 15 sec hold, 10 stretches/session/day. Wrist extensors Isometric: resistance 5 to 10 seconds, 15 contractions/ session/day.~Patients will be treated 3 times a week for 2 consecutive weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mill's Manipulation and Muscle Energy Technique
Description: Mill's Manipulation:The therapist should apply a high-velocity low-amplitude thrust accompanied by a single application . Patients will be treated 3 times a week for 2 consecutive weeks.~Muscle Energy Technique: Extensor carpi radialis stretch for 30 sec repeated 5 times during a single treatment session. Patients will be treated 3 times a week for 2 consecutive weeks.~Conventional Therapy:~Ultrasound therapy: Frequency: 1Mhz Pulse ultrasound: 1:4 Intensity: 1.5 W/cm2 Duration: 5min.~Stretching of Wrist Extensors, 15 sec hold, 10 stretches/session/day. Wrist Extensors Isometric, resistance 5 to 10 seconds, 15 contractions/ session/day.~Patients will be treated 3 times a week for 2 consecutive weeks.
Study: NCT04532502

Intervention type: DRUG
Intervention: Anesthetics, Inhalation
Description: Work environmental exposure
Study: NCT04907929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: targeted speech and cognitive therapy
Description: One month of targeted speech and cognitive therapy with a speech therapist and with home exercice at home by using a numeric solution
Study: NCT04838652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Chemotherapy (ICE or DHAP)
Description: Pembrolizumab (200mg) alone or in combination with ICE (or DHAP in case of PET positive findings after P-ICE) will be admistered. 6 additional courses of pembrolizumab will be administered after the completion P-ICE or P-DHAP